Franzoi Maria Alice

It is so good and exciting to work everyday in something that we truly believe. Forever grateful for the opportunity @ines_vazluis @ConquerCancerFd @GR_SurvOnc @GustaveRoussy @BCRFcure

Enhancing Patient Navigation with Technology to Improve Equity in Cancer Care - ⁦@PresCancerPanel⁩ ⁦@oncologynursing⁩ ⁦@OncNav⁩ prescancerpanel.cancer.gov/reports-meetin…

Had a wonderful 2 days in NYC at the @BCRFcure annual scientific conference. Enjoyed the opportunity to network and collaborate with other funded #breastcancer investigators @AliceFranzoi @GuiNaderMarta @DrLolaFayanju @oesterreichs @ChristineDesme2 @ConquerCancerFd @ASCO #bcsm

#ESMO24: Breastfeeding after #BreastCancer is feasible and safe. New data suggesting no signals that breastfeeding compromises the outcome of #BreastCancer will be valuable in guiding patient-centred decisions @AliceFranzoi #ESMODailyReporter 📌ow.ly/mgBL50TnsnY

@BlondeauxEva @AliceFranzoi @fedrophd @etop_ibcsg @BIGagainstBC

Don't miss today the proferred session on supportive care at 2:45 pm Awaited resuslts on the impact of #breastfeeding after BC 👩‍🍼 @fedrophd ➡️ results in POSITIVE trial @BlondeauxEva ➡️ results in BRCA carriers (BRCA BCY) @matteolambe @AliceFranzoi @ElisaAgostinett @OncoAlert

@GustaveRoussy @BCRFcure @ConquerCancerFd @Resiliencecare @ines_vazluis @marti_pagliuca @Thomas_Grellety @ajrsferreira

Excited to share insights from our 2-year journey co-designing and implementing a remote symptom monitoring pathway that integrates ePRO, nurse navigation, and patient education across 33 European centers. Read the full publication here: thelancet.com/journals/lanep…

Innovation in oncology isn’t just about new treatments-it’s also about how we deliver care.

📰 Les bénéfices de la télésurveillance en oncologie se confirment à grande échelle. Publiée dans @TheLancet Regional Health – Europe mercredi 31 juillet, l’étude ✨Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium✨ démontre pour la première fois dans un contexte multicentrique européen l’intérêt et la mise en œuvre d’un suivi numérique à distance en soins courants de patients pour améliorer la gestion des symptômes liés au cancer. La Dr @AliceFranzoi, médecin-chercheure à @GustaveRoussy, en est la première auteure. En savoir plus : gustaveroussy.fr/fr/news-les-be… Merci à l'application #Resilience pour cette étude. 🙏

Finally @ines_vazluis discusses how we can move survivorship care forward #MASCC24: 🧐 use data to identify those at ⬆️ risk ⏰ timely, regular assessment of concerns ✅ empower patients to self monitor and manage 💻 use digital solutions to support care 🤝 coordinate care

More on co-design and pilot testing at @MASCC: a webplatform to accelerate decentralized research - collection of multimodal patient-generated data, activation of communities of patients & researchers, toolkits for co-design, engagement, and equity. @WeShare_Onco @ines_vazluis

- Let us talk about risk! Do you assess, communicate and act on individual risk of long term toxicities of your pts since diagnosis? At @MASCC we presented a pathway co-designed with pts & providers to tackle this need and incorporate risk prediction algorithms in clinical care.

Complex interventions require inclusive co-design and careful exploration, preparation, implementation. At @MASCC we presented the development of digitally-enabled behavioural interventions: PA, meditation, yoga, CBT for fatigue, anxiety, hot flashes, fear of recurrence & more.

@GRocqueMD Great job, 100% agree

Very happy to see this one in press, we will need new strategies to engage diverse populations in #ePROs ascopubs.org/doi/10.1200/OP…

Ines Vas Luiz on the need for better characterization and addesssing of emerging therapy tox. #supponc #MASCC24

Very happy that our study on socioeconomic inequalities in quality of life (QoL) for patients with early breast cancer (EBC) from the CANTO Study is finally out at @JCO_ASCO. ascopubs.org/doi/10.1200/JC… 👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼 🔎Setting: • ~5900 women with EBC • Treated in multiple French🇫🇷 institutions • QoL assessment (EORTC-QLQ-C30 and BR23) at diagnosis, Year 1, and Year 2 • Socioeconomic status (SES) indicators: financial difficulties, income, education • Covariates: age, comorbidities, stage, detailed treatment characteristics • Country with UHC and equal access to treatment Main Findings: • Pre-existing SES inequalities in QoL widen in the 2 years after diagnosis. • Independent of age, stage at diagnosis, and received treatment. Conclusions: • The QoL burden of EBC diagnosis and treatment is heavier in women with lower SES, • Irrespective of received treatment and disease severity • UHC and equal access are not enough to prevent inequality widening. • SES-adapted interventions are needed to, at least, prevent the widening of QoL inequalities following diagnosis and primary treatment of EBC. This work wouldn't be possible without the participants in the CANTO Study, brilliantly led by @ines_vazluis (@GR_SurvOnc). Thank you to all who greatly contributed at @unige_en @UNIGEnews @hug_ge @DOncologie (@iguessous, @silviast9) and @GustaveRoussy @GroupeUnicancer @Inserm (@AliceFranzoi, @dimeglio_anto, @ajrsferreira, @FAndreMD), and especially @GwennM11 who supervised the project.

Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… New CANTO data out! @DSoldatoMD Lee Jones, @GroupeUnicancer @FAndreMD @dimeglio_anto @marti_pagliuca @AliceFranzoi @GR_SurvOnc

Dr @AliceFranzoi #ASCO24 presents on remote patient monitoring with ePROs & screening for #SDOH in routine care. The vast majority had at least 1 unfavorable SDOH ...those with actionable unfavorable SDOH had lower engagement and higher symptom burden. Interventions are needed.

Seeing my ex-fellows - @AliceFranzoi and @matteolambe - and current fellow @Lucarecco shining at @ASCO #ASCO24 is so rewarding @JulesBordet @ULBRecherche @myESMO @OncoAlert @mybsmo